Turning Point Therapeutics, Inc.
TPTXDelisted Aug 17, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595893
Turning Point Therapeutics, Inc. was delisted on Aug 17, 2022; its insiders filed their last Form 4 on Aug 17, 2022; 209 institutions reported holding it in 13F filings for Q2 2022, worth $3.29B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 209
- Q2 2022, +58 vs. previous quarter
- 13F value
- $3.29B
- Reported value at the end of Q2 2022
- Superinvestors holding
- 1
- At the end of Q2 2022
Superinvestors holding TPTX, Q2 2022
1 superinvestor reports holding Turning Point Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
1.2%
Turning Point Therapeutics, Inc.'s share of the portfolio
- Shares
- 821,635
- Value
- $61.8M
Latest insider trades
Open-market purchases and sales by Turning Point Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2022 (view filing) | Jul 27 | 2 days | Tombesi PaoloEVP & Chief Financial Officer | SSale | −1.18K | $74.94 | −$88.7K | −4.0%28.7K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Reich SiegfriedEVP & Chief Scientific Officer | SSale | −397 | $36.30 | −$14.4K | −10.3%3.45K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Partridge Andrew JohnEVP & Chief Commercial Officer | SSale | −221 | $36.30 | −$8.02K | −1.0%22.1K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | North AnnetteEVP & General Counsel | SSale | −669 | $36.30 | −$24.3K | −5.4%11.7K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Hirmand MohammadEVP & Chief Medical Officer | SSale | −669 | $36.30 | −$24.3K | −8.9%6.84K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Countouriotis AthenaPresident & CEO | SSale | −2.97K | $36.30 | −$107.8K | −5.8%47.9K after | |
| Aug 31, 2021 (view filing) | Aug 30 | 1 day | North AnnetteEVP, General Counsel & Secty. | SSale | −10.0K | $80.00 | −$800.0K | −44.7%12.4K after | |
| Jul 15, 2021 (view filing) | Jul 14 | 1 day | Partridge Andrew JohnEVP & Chief Commercial Officer | SSale | −1.87K | $74.90 | −$140.0K | −7.9%21.8K after |
Top 10 13F holders, Q2 2022
The largest institutional positions in Turning Point Therapeutics, Inc. at the end of Q2 2022; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 4,157,552 | $312.9M | 0.01% | +244,424+6.2% | Added |
| BlackRock Inc. | 3,791,801 | $285.3M | 0.01% | +99,587+2.7% | Added |
| Cormorant Asset Management, LP | 2,484,220 | $186.9M | 14.50% | −1,215,780−32.9% | Reduced |
| OrbiMed Advisors LLC | 2,012,250 | $151.4M | 2.94% | −6,700−0.3% | Reduced |
| Wellington Management Group LLP | 1,910,170 | $143.7M | 0.03% | −2,120,821−52.6% | Reduced |
| State Street Corp | 1,650,689 | $124.2M | 0.01% | −1,469,237−47.1% | Reduced |
| FIL Ltd | 1,163,475 | $87.6M | 0.10% | +1,163,475 | New |
| Farallon Capital Management, L.L.C. | 1,160,000 | $87.3M | 0.51% | +1,160,000 | New |
| Alpine Associates Management Inc. | 1,028,400 | $77.4M | 2.91% | +1,028,400 | New |
| Price T Rowe Associates Inc | 953,914 | $71.8M | 0.01% | −3,008,738−75.9% | Reduced |